Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).

Authors

Emmanuel S. Antonarakis

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Emmanuel S. Antonarakis , Adam Kibel , Robert Claude Tyler , Candice McCoy , Yang Wang , Nadeem A. Sheikh , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.

First Author: Emmanuel S. Antonarakis

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

Antigen-specific immune responses  through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).

First Author: Emmanuel S. Antonarakis

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial.

First Author: John Nikitas

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

First Author: Catherine Handy Marshall